FFR
Generated by GPT-5-miniExpansion Funnel Raw 45 → Dedup 0 → NER 0 → Enqueued 0
| FFR | |
|---|---|
| Name | FFR |
| Specialty | Cardiology |
| Test type | Diagnostic test |
| Purpose | Coronary artery disease evaluation |
| Introduced | 1990s |
FFR Fractional flow reserve (FFR) is an invasive physiological index used to assess the hemodynamic significance of coronary artery lesions. It complements imaging and angiographic evaluation by providing lesion-specific functional information to guide revascularization decisions. Developed and validated through randomized trials and multicenter registries, FFR is integrated into practice guidelines and interventional pathways worldwide.
Definition and Terminology
FFR is defined as the ratio of maximal blood flow in a stenotic coronary artery to maximal flow if that artery were normal, measured during pharmacologically induced hyperemia. Terminology associated with FFR includes hyperemic agents such as Adenosine, measurement equipment like pressure wires produced by St. Jude Medical and Abbott Laboratories, and cutoff values (classically ≤0.80) derived from outcome studies including DEFER trial, FAME trial, and FAME 2 trial. Related physiological indices include instantaneous wave-free ratio (iFR) developed by teams at University of Leicester and commercialized by Philips and resting indices like restingPd/Pa used in trials such as DEFINE-FLAIR.
History and Development
The concept of lesion-specific coronary physiology traces to seminal hemodynamic work at institutions including Université de Montréal and Cleveland Clinic in the late 20th century. Early animal and human experiments by investigators associated with John Hopkins University and Columbia University refined pressure-derived indices. The formal clinical adoption accelerated after pivotal studies: the DEFER trial demonstrated safety of deferring percutaneous coronary intervention (PCI) for FFR >0.75, while the FAME trial and FAME 2 trial—multicenter randomized studies sponsored by collaborative consortia and industry partners—established outcome benefits when FFR guided PCI using devices from Boston Scientific and Medtronic. Subsequent guideline endorsements from bodies such as the European Society of Cardiology and the American College of Cardiology cemented FFR’s role.
Methodology and Measurement
FFR measurement requires a pressure-sensing guidewire positioned distal to a coronary stenosis, simultaneous recording of aortic pressure from a guiding catheter, and induction of maximal hyperemia using agents like Adenosine administered intravenously or intracoronarily. Key procedural steps were standardized in protocols from academic centers such as Mayo Clinic and Mount Sinai Hospital. Alternative hyperemic stimulants include Regadenoson and Papaverine; nonhyperemic indices such as iFR were evaluated in trials like DEFINE-FLAIR and iFR-SWEDEHEART comparing to FFR methodologies. Quality assurance involves calibration, equalization, waveform assessment, and pullback maneuvers described in consensus documents from organizations including the European Association of Percutaneous Cardiovascular Interventions.
Clinical Applications and Indications
FFR is indicated for intermediate angiographic lesions where the physiological significance is uncertain, in multivessel coronary artery disease evaluated at centers like Cleveland Clinic or Charité – Universitätsmedizin Berlin, and during assessment of serial lesions or diffuse disease. It is used to guide decisions between PCI with stents from Abbott Laboratories or Boston Scientific, coronary artery bypass grafting involving teams at St Bartholomew's Hospital and Brigham and Women's Hospital, or medical therapy informed by trials such as COURAGE trial. FFR is applied in acute coronary syndromes to evaluate nonculprit lesions, and in assessment of myocardial bridging and left main disease as reported in registries from University College London Hospitals.
Interpretation and Diagnostic Accuracy
Interpretation relies on threshold values derived from outcome and diagnostic studies: values ≤0.80 generally indicate ischemia-producing lesions warranting revascularization, while >0.80 suggests deferral. Diagnostic accuracy was benchmarked against noninvasive modalities including Single-photon emission computed tomography centers, Cardiac magnetic resonance imaging programs at University Hospital Zurich, and invasive standards like pressure wire–derived indices. Meta-analyses incorporating data from multicenter trials and registries sponsored by collaboratives such as the European Heart Journal contributors established prognostic links between FFR-guided strategies and reductions in major adverse cardiac events.
Limitations and Risks
Limitations include dependence on adequate hyperemia, hemodynamic variability influenced by conditions treated at institutions like Massachusetts General Hospital and Toronto General Hospital, and potential measurement errors from wire drift or catheter damping documented by technical reports from St. Jude Medical. Risks are those of invasive coronary angiography: vascular access complications, coronary dissection or perforation, arrhythmia, and adverse reactions to hyperemic agents such as bronchospasm in patients with a history documented by specialist clinics at Royal Brompton Hospital. Contraindications and patient selection considerations have been addressed in position statements by the Society for Cardiovascular Angiography and Interventions.
Future Directions and Research
Current research directions include noninvasive FFR estimation from computed tomography angiography (FFR-CT) developed by companies like HeartFlow and evaluated against invasive FFR in multicenter studies involving centers such as Johns Hopkins Hospital and Imperial College London. Machine learning approaches incorporating datasets from registries at Duke University Medical Center and wearable physiologic monitoring are under investigation. Ongoing trials compare hybrid strategies combining iFR and FFR, evaluate cost-effectiveness in health systems such as the National Health Service, and assess long-term outcomes in cohorts enrolled by consortia including the Cardiovascular Research Foundation.